Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma

Drug resistance remains the key problem in cancer treatment. It is now accepted that each myeloma patient harbors multiple subclones and subclone dominance may change over time. The coexistence of multiple subclones with high or low chromosomal instability (CIN) signature causes heterogeneity and dr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Invest
Main Authors: Franqui-Machin, Reinaldo, Hao, Mu, Bai, Hua, Gu, Zhimin, Zhan, Xin, Habelhah, Hasem, Jethava, Yogesh, Qiu, Lugui, Frech, Ivana, Tricot, Guido, Zhan, Fenghuang
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2018
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6026005/
https://ncbi.nlm.nih.gov/pubmed/29863498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI98765
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki